US3773719A
(en)
|
1966-12-06 |
1973-11-20 |
Hoffmann La Roche |
2-aminoxy-2'-acyl-acetanilide
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
DE3785186T2
(en)
|
1986-09-02 |
1993-07-15 |
Enzon Lab Inc |
BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
DE3883899T3
(en)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
CHANGED ANTIBODIES.
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
CS269411B1
(en)
|
1988-09-14 |
1990-04-11 |
Ales Manek |
Device for yearn's interruption
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
CA2109602C
(en)
|
1990-07-10 |
2002-10-01 |
Gregory P. Winter |
Methods for producing members of specific binding pairs
|
KR100272077B1
(en)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
Transgenic non-human animals capable of producing heterologous antibodies
|
KR100249937B1
(en)
|
1991-04-25 |
2000-04-01 |
나가야마 오사무 |
Reshaped human antibody to human interleukin-6 receptor
|
DK0605522T3
(en)
|
1991-09-23 |
2000-01-17 |
Medical Res Council |
Process for producing humanized antibodies
|
US6025165A
(en)
|
1991-11-25 |
2000-02-15 |
Enzon, Inc. |
Methods for producing multivalent antigen-binding proteins
|
ATE275198T1
(en)
|
1991-12-02 |
2004-09-15 |
Medical Res Council |
PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
|
JPH07503132A
(en)
|
1991-12-17 |
1995-04-06 |
ジェンファーム インターナショナル,インコーポレイティド |
Transgenic non-human animals capable of producing xenoantibodies
|
CA2131151A1
(en)
|
1992-03-24 |
1994-09-30 |
Kevin S. Johnson |
Methods for producing members of specific binding pairs
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
JPH07509137A
(en)
|
1992-07-24 |
1995-10-12 |
セル ジェネシス,インク. |
Production of xenoantibodies
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
US5648267A
(en)
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
EP0754225A4
(en)
|
1993-04-26 |
2001-01-31 |
Genpharm Int |
Transgenic non-human animals capable of producing heterologous antibodies
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
WO1995015388A1
(en)
|
1993-12-03 |
1995-06-08 |
Medical Research Council |
Recombinant binding proteins and peptides
|
DE122009000068I2
(en)
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Process for the preparation of heterologous bispecific antibodies
|
WO1996002576A1
(en)
|
1994-07-13 |
1996-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin-8
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
CN101601861A
(en)
|
1994-10-07 |
2009-12-16 |
中外制药株式会社 |
Treat chronic rheumatoid arthritis with the IL-6 antagonist as effective ingredient
|
HU227708B1
(en)
|
1994-10-21 |
2011-12-28 |
Chugai Pharmaceutical Co Ltd |
Use of anti-interleukin-6-receptor antibodies mr-16 and pm-1 and derivatives thereof for producing pharmaceutical preparation for treating diseases caused by il-6 production
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
CA2210309C
(en)
|
1995-02-28 |
2002-04-16 |
The Procter & Gamble Company |
Preparation of noncarbonated beverage products having superior microbial stability
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
DE69637481T2
(en)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Human antibodies to IL-8 derived from immunized Xenomae
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
Human antibodies derived from immunized xenomice
|
AU690474B2
(en)
|
1995-09-11 |
1998-04-23 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody againts alpha-chain of human interleukin 5 receptor
|
US6211150B1
(en)
|
1996-07-19 |
2001-04-03 |
Amgen Inc. |
Analogs of cationic proteins
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
ES2246069T3
(en)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
JP3992298B2
(en)
|
1997-10-03 |
2007-10-17 |
中外製薬株式会社 |
Natural humanized antibody
|
WO1999051743A1
(en)
|
1998-04-03 |
1999-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
CA2341029A1
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
WO2000018806A1
(en)
|
1998-09-25 |
2000-04-06 |
Horst Lindhofer |
Bispecific and trispecific antibodies which specifically react with inducible surface antigens as operational target structures
|
JP2002531466A
(en)
|
1998-12-01 |
2002-09-24 |
プロテイン デザイン ラブス, インコーポレイテッド |
Humanized antibodies to gamma interferon
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
JP2003512019A
(en)
|
1999-01-15 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
Polypeptide variants with altered effector functions
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SE9903895D0
(en)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
WO2001082899A2
(en)
|
2000-05-03 |
2001-11-08 |
Mbt Munich Biotechnology Ag |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
JP4336498B2
(en)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
Molecules with extended half-life and compositions and uses thereof
|
CN1294148C
(en)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
Single-stranded cyctic trispecific antibody
|
CA2443903C
(en)
|
2001-04-13 |
2018-03-20 |
Biogen, Inc. |
Antibodies to vla-1
|
DK1411118T3
(en)
|
2001-06-22 |
2008-11-17 |
Chugai Pharmaceutical Co Ltd |
Cell proliferation inhibitors containing anti-glypican-3 antibody
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
ES2326964T3
(en)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
GLICOPROTEIN COMPOSITIONS.
|
AU2003216250A1
(en)
|
2002-02-11 |
2003-09-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
WO2003107218A1
(en)
|
2002-05-31 |
2003-12-24 |
セレスター・レキシコ・サイエンシズ株式会社 |
Interaction predicting device
|
JP2004086862A
(en)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
Apparatus, method and program for processing protein interaction information, and recording medium
|
JP3991280B2
(en)
|
2002-06-05 |
2007-10-17 |
中外製薬株式会社 |
Antibody production method
|
PT1517921E
(en)
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM
|
JP2005535341A
(en)
|
2002-08-15 |
2005-11-24 |
エピトミスク インコーポレーティッド |
Humanized rabbit antibody
|
AU2002328429A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
LT3284753T
(en)
|
2002-10-17 |
2020-06-10 |
Genmab A/S |
Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
|
DE602004021095D1
(en)
|
2003-01-21 |
2009-06-25 |
Chugai Pharmaceutical Co Ltd |
METHOD OF SCREENING THE LIGHT CHAIN OF AN ANTIBODY
|
CA2515081A1
(en)
|
2003-02-07 |
2004-08-19 |
Protein Design Labs, Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
KR20120104408A
(en)
*
|
2003-05-30 |
2012-09-20 |
제넨테크, 인크. |
Treatment with anti-vegf antibodies
|
PT1631313E
(en)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Combination therapy for b cell disorders
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
EP1711207B1
(en)
|
2003-12-10 |
2012-11-28 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
DE602005026779D1
(en)
|
2004-01-09 |
2011-04-21 |
Pfizer |
ANTIBODIES AGAINST MAdCAM
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
SG10201606980VA
(en)
|
2004-06-03 |
2016-10-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
KR100620554B1
(en)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
-72 Humanized Anti-TAG-72 Monoclonal Antibodies
|
AR049390A1
(en)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
|
JP2008504289A
(en)
|
2004-06-25 |
2008-02-14 |
メディミューン,インコーポレーテッド |
Increased production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
EP2898897A3
(en)
|
2004-07-09 |
2015-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody
|
BRPI0510674A
(en)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
optimized fc variants
|
EA012464B1
(en)
|
2004-08-04 |
2009-10-30 |
Эпплайд Молекьюлар Эволюшн, Инк. |
Antibody against cd20 and use thereof
|
EP1789446A2
(en)
|
2004-09-02 |
2007-05-30 |
Genentech, Inc. |
Heteromultimeric molecules
|
US7572456B2
(en)
|
2004-09-13 |
2009-08-11 |
Macrogenics, Inc. |
Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
|
CA2580319A1
(en)
|
2004-09-14 |
2006-03-23 |
National Institute For Biological Standards And Control |
Vaccine
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
EP1829961A4
(en)
|
2004-12-22 |
2008-06-04 |
Chugai Pharmaceutical Co Ltd |
Method of preparing antibody by use of cell having its fucose transporter function inhibited
|
US20060275282A1
(en)
|
2005-01-12 |
2006-12-07 |
Xencor, Inc. |
Antibodies and Fc fusion proteins with altered immunogenicity
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
EP1871808A2
(en)
|
2005-03-31 |
2008-01-02 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
CA2603264C
(en)
|
2005-04-08 |
2017-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
EP1925319B1
(en)
|
2005-06-10 |
2018-03-07 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(fv)2
|
WO2006132341A1
(en)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
PT2407486T
(en)
|
2005-08-19 |
2018-02-21 |
Univ Pennsylvania |
Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
CA2646965C
(en)
|
2006-03-24 |
2016-06-21 |
Jonathan H. Davis |
Engineered heterodimeric protein domains
|
KR101463631B1
(en)
|
2006-03-31 |
2014-11-19 |
추가이 세이야쿠 가부시키가이샤 |
Method for control of blood kinetics of antibody
|
WO2007114325A1
(en)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
WO2007145941A2
(en)
|
2006-06-06 |
2007-12-21 |
Tolerrx, Inc. |
Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
US20110236374A1
(en)
|
2007-01-24 |
2011-09-29 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
ES2667863T3
(en)
|
2007-03-29 |
2018-05-14 |
Genmab A/S |
Bispecific antibodies and their production methods
|
US8337854B2
(en)
|
2007-04-04 |
2012-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Monoclonal antibodies against dengue and other viruses with deletion in Fc region
|
EP4119579A1
(en)
|
2007-05-31 |
2023-01-18 |
Genmab A/S |
Stable igg4 antibodies
|
CA2691618A1
(en)
|
2007-06-29 |
2009-01-08 |
Schering Corporation |
Mdl-1 uses
|
EP2178921B1
(en)
|
2007-07-17 |
2016-01-06 |
E. R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against glypican-3
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
RU2526512C2
(en)
|
2007-09-26 |
2014-08-20 |
Чугаи Сейяку Кабусики Кайся |
Modified constant region of antibody
|
RU2505603C2
(en)
|
2007-09-26 |
2014-01-27 |
Чугаи Сейяку Кабусики Кайся |
Antibody against il-6 receptor
|
KR20100085067A
(en)
|
2007-09-28 |
2010-07-28 |
추가이 세이야쿠 가부시키가이샤 |
Anti-glypican-3 antibody having improved kinetics in plasma
|
JP5314033B2
(en)
|
2007-10-22 |
2013-10-16 |
メルク セローノ ソシエテ アノニム |
Single IFN-beta fused to mutant IgG Fc fragment
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
SI2274008T1
(en)
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
PL2708558T3
(en)
|
2008-04-11 |
2018-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
KR20110047255A
(en)
|
2008-09-26 |
2011-05-06 |
로슈 글리카트 아게 |
Bispecific Anti-EGFF / Anti-IFF-1R Antibody
|
NZ592611A
(en)
|
2008-10-10 |
2013-01-25 |
Emergent Product Dev Seattle |
A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
|
DE202008016028U1
(en)
|
2008-12-04 |
2010-04-15 |
Melitta Haushaltsprodukte Gmbh & Co. Kg |
Containers for storing objects
|
EP2389192A4
(en)
|
2009-01-23 |
2013-01-16 |
Biogen Idec Inc |
Stabilized fc polypeptides with reduced effector function and methods of use
|
EP2772269A3
(en)
|
2009-03-05 |
2015-01-14 |
Abbvie Inc. |
IL-17 binding proteins
|
WO2010107110A1
(en)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
Antibody constant region variant
|
TWI646193B
(en)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
Antibody constant region alteration
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
JP6132548B2
(en)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
EP2417156B1
(en)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalent, bispecific antibodies
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
MY152963A
(en)
|
2009-06-26 |
2014-12-15 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
JP5903382B2
(en)
|
2009-08-29 |
2016-04-13 |
アッヴィ・インコーポレイテッド |
Therapeutic DLL4 binding protein
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
BR112012017124C1
(en)
|
2009-12-25 |
2021-08-31 |
Chugai Pharmaceutical Co Ltd |
Method for making and purifying a polypeptide multimer
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
JP5820800B2
(en)
|
2010-03-02 |
2015-11-24 |
協和発酵キリン株式会社 |
Modified antibody composition
|
JP5889181B2
(en)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
Antibody constant region variants
|
MX2012010481A
(en)
|
2010-03-11 |
2012-10-09 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING.
|
AU2011244282A1
(en)
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
JP6048972B2
(en)
|
2010-04-23 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
Production of heteromultimeric proteins
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
EP3539988A3
(en)
|
2010-05-27 |
2019-12-04 |
Genmab A/S |
Monoclonal antibodies against her2
|
EP2603526A1
(en)
|
2010-08-13 |
2013-06-19 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
RU2608640C2
(en)
|
2010-08-16 |
2017-01-23 |
Новиммун С.А. |
Methods for generation of multispecific and multivalent antibodies
|
CN103429620B
(en)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
There is the antibody design of the stable heterodimeric of mutation in Fc domains
|
MX349057B
(en)
|
2010-11-30 |
2017-07-07 |
Chugai Pharmaceutical Co Ltd |
Cytotoxicity-inducing therapeutic agent.
|
WO2012093704A1
(en)
|
2011-01-07 |
2012-07-12 |
中外製薬株式会社 |
Method for improving physical properties of antibody
|
EP3825325A3
(en)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
CN110964115B
(en)
|
2011-10-27 |
2024-03-12 |
健玛保 |
Production of heterodimeric proteins
|
CA2853230C
(en)
|
2011-10-31 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
CN104080811B
(en)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain
|
WO2014067011A1
(en)
|
2012-11-02 |
2014-05-08 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
SG11201406346SA
(en)
|
2012-04-20 |
2014-11-27 |
Emergent Product Dev Seattle |
Cd3 binding polypeptides
|
AU2013249985B2
(en)
|
2012-04-20 |
2017-11-23 |
Merus N.V. |
Methods and means for the production of Ig-like molecules
|
US20130336973A1
(en)
|
2012-05-10 |
2013-12-19 |
Zymeworks Inc. |
Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
|
WO2013181543A1
(en)
|
2012-06-01 |
2013-12-05 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
IN2015DN01299A
(en)
|
2012-07-23 |
2015-07-03 |
Zymeworks Inc |
|
JP6309521B2
(en)
|
2012-08-13 |
2018-04-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Anti-PCSK9 antibody with pH-dependent binding properties
|
JOP20200236A1
(en)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
|
DK2900694T3
(en)
|
2012-09-27 |
2018-11-19 |
Merus Nv |
BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
|
ES2773107T3
(en)
|
2012-10-05 |
2020-07-09 |
Kyowa Kirin Co Ltd |
Heterodimeric protein composition
|
CN103833852A
(en)
|
2012-11-23 |
2014-06-04 |
上海市肿瘤研究所 |
Bispecific antibody aiming at phosphatidylinositols protein polysaccharide-3 and T cell antigen
|
EP3050896B1
(en)
|
2013-09-27 |
2021-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
EP3037525B1
(en)
|
2013-09-30 |
2021-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing antigen-binding molecule using modified helper phage
|
RU2722788C2
(en)
|
2014-04-07 |
2020-06-03 |
Чугаи Сейяку Кабусики Кайся |
Immunoactivating antigen-binding molecule
|
MX2016014434A
(en)
*
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
T cell-redirected antigen-binding molecule for cells having immunosuppression function.
|
MA40764A
(en)
*
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
US11612149B2
(en)
|
2015-07-10 |
2023-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
Non-human animal having human CD3 gene substituted for endogenous CD3 gene
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
MY196747A
(en)
|
2016-03-14 |
2023-05-03 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
TWI667254B
(en)
|
2017-09-29 |
2019-08-01 |
日商中外製藥股份有限公司 |
Multispecific antigen-binding molecule with functional replacement factor VIII coagulation factor (FVIII) and pharmaceutical preparation containing the molecule
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
JP7444790B2
(en)
|
2018-05-16 |
2024-03-06 |
ヤンセン バイオテツク,インコーポレーテツド |
Methods of treating cancer and improving the effectiveness of T cell redirection therapeutics
|